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Abstract: Parkinson disease (PD) is a neurodegenerative disorder characterized by 3 cardinal 
motor symptoms: resting tremor, rigidity, and bradykinesia. Since its introduction 40 years ago, 
levodopa has represented the gold standard for dopaminergic stimulation therapy in patients with 
PD. Levodopa is routinely combined with a dopa-decarboxylase inhibitor (DDCI) to prevent the 
conversion of levodopa into dopamine in peripheral circulation. However, up to 80% of patients 
treated with continuous levodopa manifest the onset of disabling motor complications capable 
of producing an adverse effect on quality of life as the disease progresses. In recent years, a new, 
safe, and efficacious armamentarium of treatment options has been provided by the marketing of 
the catechol-O-methyltransferase (COMT) inhibitor, entacapone, a peripheral blocker of dopa to 
3-0-methyldopa metabolism, which increments levodopa brain availability. When administered 
with levodopa, entacapone conjugates the rapid onset of levodopa-induced effects with a protracted 
efficiency, thus providing additional benefits to classic levodopa treatment by increasing “on” time 
in fluctuating PD patients, and theoretically providing a more continuous and physiological-like 
stimulation of dopamine receptors implying a reduced risk of motor complications. In this con-
text, the use of a single administration of combined   carbidopa/levodopa/entacapone (Stalevo®) in 
the treatment of PD affords clinical improvements similar to those obtained by 2 separate tablets 
(ie, levodopa/DDCI and entacapone), although the former produces a more positive effect on quality 
of life than the latter. Additionally, the STalevo Reduction In Dyskinesia Evaluation (STRIDE-PD) 
study was designed with the aim of demonstrating that the combination of levodopa, carbidopa, 
and entacapone, used as initial levodopa therapy, significantly delays the onset of dyskinesias 
compared with the conventional levodopa/carbidopa formulation. Unfortunately, STRIDE-
PD failed to prove the benefit of continuous dopaminergic stimulation with triple therapy in a 
  clinical setting. Recently, the effect of combined COMT inhibitor with levodopa administration 
in   reducing homocysteine synthesis has been described. To this regard, clear evidence has been 
presented indicating homocysteine as a risk factor for vascular diseases, cognitive impairment, 
and dementia. Several studies have discussed the potential of entacapone as adjunct to levodopa/
DDCI in reducing plasma homocysteine levels with contrasting results.
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Introduction
Parkinson disease (PD) is a neurodegenerative disorder characterized by 3 cardinal 
motor symptoms: resting tremor, rigidity, and bradykinesia,1 affecting   approximately 
1% of subjects older than 60 years and representing the second most common 
  neurodegenerative disorder (after Alzheimer disease) in this population.2,3Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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Since its introduction 40 years ago, levodopa has constituted 
the most efficacious and well-tolerated symptomatic treatment 
for dopaminergic stimulation therapy in patients with PD.4
Levodopa is routinely combined with a dopa-  decarboxylase 
inhibitor (DDCI; Figure 1), either carbidopa (Sinemet®) or 
benserazide (Madopar®), to prevent the conversion of levodopa 
into dopamine in the peripheral circulation, thereby allowing 
a greater quantity of levodopa to reach the brain after active 
transport across the blood–brain barrier.5 However, as the dis-
ease progresses, up to 80% of patients who continued to receive 
levodopa treatment experience the onset of disabling motor 
complications, such as “wearing-off” symptoms, dyskinesias, 
and “on–off” mobility patterns.6 Approximately 10% of PD 
patients per year develop motor complications after starting 
levodopa treatment, which increases to almost 100% of patients 
after 10 years of levodopa therapy.7,8 A retrospective analysis of 
the CALM-PD (Comparison of the agonist pramipexole with 
levodopa on motor complications of Parkinson’s disease) study 
estimated an incidence of motor fluctuations within a range of 
12%–60% and an incidence of dyskinesias from 8% to 64% 
after 4–6 years of levodopa treatment.9 Although the pathogen-
esis of these motor fluctuations is not completely understood, 
these effects are presumably related to the short half-life of 
levodopa, perhaps as a function of a nonphysiological, pulsatile 
stimulation of dopamine receptors.10–12 These complications 
may become severely disabling, producing a profound effect 
on patients’ and caregivers’ quality of life and representing a 
major   challenge in the long-term treatment of patients with 
PD. In order to delay or prevent levodopa-induced complica-
tions, several therapeutic strategies are commonly used to 
manage these symptoms,13 providing cumulating evidence that 
continuous nigrostriatal postsynaptic dopaminergic receptor 
stimulation may prevent the onset of these complications.14
Drugs used in the management  
of motor complications
Many parkinsonologists recommend dopamine agonist (DA) 
drugs, such as bromocriptine, pergolide, cabergoline, lisuride, 
apomorphine, pramipexole, ropinirole, and rotigotine, as ini-
tial dopaminergic therapy,15 with the aim of improving motor 
response and decreasing “off” time, supposedly through direct 
stimulation of dopamine receptors. Based on a consistent body 
of evidence from randomised controlled trials, the DA drugs 
dihydroergocryptine, pergolide, pramipexole, ropinirole, and 
rotigotine, used as monotherapy, have all been shown to be an 
effective symptomatic treatment in the early stages of PD,16–20 
delaying the introduction of levodopa by several months or 
years.21 Moreover, PD patients treated with DAs including 
pergolide,22 cabergoline,23 pramipexole,24,25 and ropinirole26 
have been compared with patients treated with levodopa in 
large, double-blind, randomized trials, revealing a significantly 
reduced risk of motor   complications, such as dyskinesias over 
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follow-up periods of up to 5 years. Indeed, DAs are also used 
as first-line drugs in adjunct therapy in patients treated with 
levodopa presenting motor fluctuations. The efficacy of DAs 
in reducing motor   complications is believed to be a result of 
their long   half-lives, leading to increasingly constant plasma 
concentrations and hence a reduction in pulsatile striatal dop-
amine receptor stimulation. On the basis of preclinical studies 
highlighting the potential neuroprotective activity of DAs, 
these drugs have been investigated for their putative disease-
modifying effects. To this regard, 2 double-blind randomized 
trials,27,28 with in vivo imaging using either F-dopa/positron 
emission tomography (PET) or β-CIT/single photon emis-
sion computed tomography (SPECT), have been performed 
to evaluate the progressive loss of dopaminergic neurons in 
patients with early PD. These 2 imaging studies, using ropini-
role (  REAL-PET) and pramipexole (CALM-PD CIT), have 
demonstrated that treatment with DAs was associated with a 
significant decrease in the rate of decline of putaminal F-dopa 
or striatal β-CIT uptake, markers of dopaminergic neuron 
degeneration, compared with that observed for levodopa. 
The findings of these trials indicated that treatment with 
ropinirole and pramipexole, compared with levodopa, may 
alter the rate of disease progression, although no conclusive 
findings were provided to determine whether the results reflect 
a neuroprotective action provided by DAs or an effect of 
levodopa-induced toxicity. Unfortunately, although effective, 
this class of medications is potentially associated with psy-
chiatric adverse effects that limit their utility.29 Furthermore, 
ergot DAs may determine severe valvular heart disease30 and 
accordingly their use has been essentially discontinued in 
medical practice.21 In addition to dopaminergic drugs, other 
nondopaminergic drugs including the N-methyl-d-aspartate 
receptor antagonist amantadine31,32 and the monoamine oxi-
dase type B (MAO-B) inhibitors,33 rasagiline and selegiline, 
are capable of affording satisfactory symptomatic relief in 
the early phases of anti-PD therapy. While amantadine, given 
in adjunct to levodopa, has been used in lowering dyskinesia 
scores and improving motor complications in patients with 
PD, the main use of MAO-B inhibitors has focused on their 
potential neuroprotective activity aimed at slowing down the 
course of the disease and preventing the onset of motor com-
plications, with a demonstrated “disease-modifying” action 
in the case of rasagiline.34,35
In addition to conventional levodopa formulations with 
DDCI, controlled-release (CR) levodopa formulations 
(levodopa/carbidopa, Sinemet CR; levodopa/benserazide, 
Madopar PR) have been developed in an attempt to   maintain 
a more stable plasma levodopa   profile, and therefore reduce 
fluctuations for some patients. In clinical practice, however, 
this approach often leads to intermittent reemergence of 
symptoms due to the pulsatile nature of levodopa delivery, 
with associated phenomena of delayed “on” time with 
erratic absorption, a factor featuring an unpredictable 
  bioavailability when compared with immediate-release 
  conventional levodopa.36 In this scenario, conflicting results 
have been described in clinical trials with some studies 
reporting significant clinical advantages over standard prepa-
rations, while others report erratic absorption and lack of 
additional therapeutic benefits,37–39 although CR-levodopa/
carbidopa may contribute towards alleviating disruptive 
nighttime symptoms.21
Furthermore, over the last few years, an innovative addi-
tion to the treatment options available has been provided by 
catechol-O-methyltransferase (COMT) inhibitors, which 
prevalently block the peripheral metabolism of levodopa to 
3-0-methyldopa (3-OMD), reducing formation of 3-OMD 
and resulting in a measurable increase in the amount of 
levodopa entering the brain (Figure 1).
Rationale for treatment with 
COMT inhibitors, entacapone,  
and tolcapone
While the first COMT inhibitors described in the 1960s40 were 
unselective, nonpotent, and considerably toxic, the 2 cur-
rently marketed COMT-inhibitors, entacapone (Comtan®), 
the only peripheral-acting compound, and the central-acting 
tolcapone (Tasmar®), are new potent, selective, and reversible 
nitrocatechol-type COMT inhibitors.41
Therefore, these agents, given adjunctively with levodopa/
DDCI, decrease levodopa turnover and increase its half-life, 
improving the area under the concentration (AUC) time–
curve and delivery of levodopa to the brain. Moreover, 
these compounds reduce the frequency of both dose and 
administration of levodopa, decreasing “off” time and 
increasing “on” time which together result in an improved, 
prolonged clinical response to levodopa.42,43 For these rea-
sons, the introduction of a COMT inhibitor combines with 
the rapid onset of levodopa to ensure protracted efficacy, 
an association theoretically providing a more continuous 
stimulation of dopamine receptors with reduced risk of motor 
complications.44 These advantages can be obtained simply 
by peripheral COMT inhibition.
Although more potent than entacapone, the COMT inhibi-
tor tolcapone is not a first-line drug, as it requires strict moni-
toring due to potential hepatotoxicity. Indeed, in the past, 
descriptions of acute, fatal fulminant hepatitis, and potentially Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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fatal neurological reactions, such as neuroleptic malignant 
syndrome and rhabdomyolysis, associated with tolcapone led 
to the withdrawal of its marketing   authorization throughout 
the European community. The safety and tolerability of 
adjunctive tolcapone started concomitant to levodopa have 
recently been evaluated, with particular focus on changes in 
liver transaminase and potential hepatotoxicity;45 therefore, 
the use of tolcapone in the European community is currently 
restricted to patients who do not respond adequately to other 
therapies.
Conversely, among COMT inhibitors, entacapone rep-
resents the drug of choice in view of its satisfactory safety 
and tolerability profile. Due to its short half-life, however, 
  entacapone requires frequent administrations,44 and a 
dose of 200 mg entacapone at each levodopa and DDCI 
  administration, up to 8 times per day, has been selected for 
clinical use mainly based on the results of a dose–response 
study.21,46 In 2003, the US Food and Drug Administration 
(FDA) approved combined carbidopa, levodopa, and entaca-
pone in a single tablet, with the brand name of Stalevo®, for 
end-of-dose wearing-off. In a randomized, crossover study of 
132 healthy subjects, the levodopa AUC was essentially the 
same when used in the triple combination vs single admin-
istration, indicating equivalent pharmacokinetics.47,48
Use of entacapone in PD
The first trials to evaluate the use of entacapone in patients 
with PD were 2 multicenter, double-blind, random-
ized, placebo-controlled 6-month studies conducted in 
North America49 and in the European Nordic countries.50 
The studies were undertaken with the aim of demonstrating 
the clinical efficacy, safety, and tolerability of entacapone 
combined with levodopa in the treatment of parkinsonian 
patients with an end-of-dose deterioration in response to 
levodopa (“the wearing-off” phenomenon). In these studies, 
entacapone 200 mg was administered in addition to each dose 
of levodopa/carbidopa or levodopa/benserazide, and both 
trials showed that entacapone was effective as an adjunct 
to levodopa. The duration of daily “on” time was increased 
by 1–1.2 hours and correspondingly the “off” times were 
decreased in patients with fluctuating PD. The effect of enta-
capone was more pronounced after the first dose, with drug 
benefits increasing throughout the day.49 Other end points in 
these pivotal trials indicated that entacapone with levodopa/
DDCI significantly improved total activities of daily living 
(ADL) and motor function scores. In line with its effect on 
levodopa pharmacokinetics, entacapone led to a reduction in 
daily levodopa dosages, which were lowered from baseline 
by 11%–16% in patients with entacapone and levodopa/
DDCI, compared with those receiving levodopa/DDCI alone. 
The beneficial effect was lost on withdrawal of   entacapone. 
  Entacapone was well tolerated. Adverse events with enta-
capone included diarrhea, urine discoloration,   confusion, 
orthostatic hypotension, and increased dyskinesias, at times 
requiring a reduction in daily levodopa dosage.
Data concerning the efficacy and tolerability of entaca-
pone over a 3-year period in PD patients were confirmed 
in a subsequent study.51 Moreover, further studies demon-
strated that entacapone was well tolerated, providing addi-
tional antiparkinsonian benefits to levodopa therapy and in 
levodopa-treated PD patients experiencing wearing-off motor 
fluctuations despite adjunct DA therapy,52 and enhancing 
the pharmacokinetic and clinical response to CR levodopa 
formulations.53 Subsequently, further studies not only con-
firmed the finding of the excellent risk/benefit ratio seen in 
phase 3 controlled studies in daily neurological practice but 
also suggested that, independent of dosing frequency, the 
benefits of levodopa/DDCI therapy with entacapone were 
associated with a significant impact on patient quality of life, 
providing clinically relevant improvements in global status 
and quality of life in PD patients experiencing wearing-off 
on their current levodopa dosing frequency.54–56
Although only fluctuating patients were recruited in the 
earlier clinical studies, the efficacy of entacapone in patients 
with stable treated PD devoid of motor fluctuations had also 
been assessed in trials such as the Celomen study, with the 
aim of obtaining more experience on the use of entacapone in 
patients with less advanced disease.57 This 6-month, random-
ized, placebo-controlled, double-blind study conducted at cen-
ters throughout Germany and Austria showed how the addition 
of entacapone to levodopa and carbidopa in the subset of PD 
patients without clear motor fluctuations modestly improved 
motor and ADL scores (respectively improving ADL scores 
from 11.3 to 10.3, and motor scores from 28.0 to 25.7) and 
allowed a reduction in levodopa by 24 ± 75 mg in the enta-
capone group compared with an increase of 2 ± 75 mg with 
placebo.
However, despite the observation of a beneficial trend in 
nonfluctuating patients treated with entacapone, the differ-
ences between the groups were not statistically significant 
due to small sample size (25 patients for entacapone and 16 
for placebo). An additional study performed at 29 sites in 
the United Kingdom and the Republic of Ireland, confirming 
the ability of entacapone to provide additional benefits to 
levodopa treatment in increasing “on” time in fluctuating PD 
patients, suggesting that the benefits afforded by   combining Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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levodopa with entacapone could be extended to patients who 
were not experiencing motor fluctuations, as evidenced by 
improved ADL scores and a relatively reduced levodopa 
requirement.58
To this regard, however, a subsequent double-blind, 
placebo-controlled, multicenter study of 750 patients   taking 
levodopa and carbidopa without motor fluctuations demon-
strated no improvement in Unified Parkinson’s Disease Rating 
Scale (UPDRS) motor or ADL scores during entacapone,59 
although several quality of life scales, as well as investigator 
and subject Clinical Global Assessment scores, indicated a 
considerable improvement.
Use of combined carbidopa/ 
levodopa/entacapone (Stalevo®) in PD
In June 2003, the FDA approved triple combination tablets 
(Stalevo; Novartis) containing carbidopa, levodopa, and 
entacapone for the treatment of patients with idiopathic PD 
experiencing signs and symptoms of end-of-dose “wearing-
off.” In a randomized, crossover study of 132 healthy subjects, 
the levodopa AUC was essentially the same when used in the 
triple combination versus single administration, indicating 
equivalent pharmacokinetics.47,48
These data were confirmed by a randomized, parallel-
group, multinational European clinical trial investigating 
the use of Stalevo in the treatment of PD.60 This study found 
that Stalevo was well tolerated by patients diagnosed with 
idiopathic PD experiencing motor fluctuations, provid-
ing similar clinical improvements to those obtained with 
2 separate tablets (ie, levodopa/DDCI and entacapone). 
Furthermore, the majority of PD patients included in this 
trial stated that they preferred treatment with Stalevo com-
pared with taking separate levodopa/DDCI and entacapone, 
resulting in a better quality of life for patients than adjunct 
entacapone.
In this regard, an open-label study in PD patients expe-
riencing wearing-off assessed the impact of switching from 
traditional levodopa/DDCI therapies with adjunctive entaca-
pone therapy to Stalevo, revealing how the majority of patients 
treated with levodopa/DDCI plus entacapone can be easily and 
successfully switched to Stalevo.61 This observation has been 
confirmed by a more recent multicenter, open-label, 6-week 
study,62 based on the patient- and investigator-assessed Clini-
cal Global Impression of Change (CGI), change from baseline 
UPDRS, motor/nonmotor wearing-off symptoms, and quality 
of life-visual analog scale, suggesting that switching from 
levodopa/carbidopa to Stalevo provided a significant benefit 
in PD patients with wearing-off.
A further trial, the FIRST-STEP study, was designed to 
demonstrate the enhanced efficacy provided by the added 
component.63 This 39-week, randomized, double-blind, 
multicenter trial, compared the efficacy and tolerability of 
the currently available triple combination tablets (Stalevo) 
containing carbidopa, levodopa, and entacapone with imme-
diate-release levodopa/carbidopa in patients with early PD. 
This study additionally aimed to demonstrate that Stalevo was 
safe in early PD patients with a need for levodopa therapy. 
Results of this trial confirmed the greater symptomatic ben-
efit provided by the use of Stalevo compared with levodopa/
carbidopa alone, demonstrating a significant difference in 
total UPDRS observed after 4 weeks, which was maintained 
throughout the 39-week observation period, with the great-
est difference occurring at week 26, without concomitant 
increase of the development of motor complications. More-
over, interestingly, the subjects’ CGI scores were significantly 
improved in the Stalevo compared with the levodopa/carbi-
dopa alone cohort, although the investigator CGI remained 
unchanged. However, two important limitations should be 
taken in account in evaluating these results. First, changes 
in Hoehn-Yahr, UPDRS motor scores, PDQ-39, and PDQ-8 
scores did not differ significantly across groups. As expressed 
by the same authors, these data might potentially reflect a 
relative insensitivity to change of these measures in early 
PD, together with the fact that the study was not   powered 
to evaluate these measures, indicating that subjects are bet-
ter able to recall their baseline status and provide a more 
accurate assessment of change than the investigator.63 The 
second limitation in the design of this study, as suggested 
by Müller,64 was the lack of comparisons with placebo and 
treatment with DAs.
In view of the concept that avoidance of troughs in 
plasma concentration of levodopa and more continuous 
nigrostriatal postsynaptic dopaminergic receptor stimulation 
could delay the occurrence and lead to a lower incidence of 
motor complications in PD patients, some trials65–70 were 
addressed to evaluate whether therapy with levodopa/
carbidopa/entacapone was more effective compared with 
standard levodopa/DDCI in reducing the onset of motor 
fluctuations when used from the beginning. This observation 
was postulated on theoretical grounds and from experimental 
research in animal models. A previous double-blind study 
with CR levodopa demonstrated how this formulation did 
not avoid low plasma levodopa trough levels and provided 
no continuous nigrostriatal postsynaptic dopaminergic recep-
tor stimulation, mainly due to its erratic absorption.71 On 
the contrary, as previously cited, entacapone provides for Neuropsychiatric Disease and Treatment 2010:6 submit your manuscript | www.dovepress.com
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more stable plasma levodopa levels with tonic stimulation of 
dopamine receptors in the striatum and, thus, might decrease 
the risk of developing motor complications.
On the basis of the observations outlined here, post hoc 
analyses of pooled data from 3 randomized, double-blind, 
clinical trials and open-label extensions49,50,57 in PD patients 
with motor complications were performed to determine 
whether early enhancement of levodopa therapy could 
lead to better long-term outcomes than delayed entacapone 
  treatment.72 Although this study was limited by the lack of 
important outcome records, final data obtained suggested 
that early rather than delayed addition of entacapone to 
levodopa/DDCI in PD patients with wearing-off provided 
a modest clinical benefit over levodopa/DDCI maintained 
for up to 5 years. In this context, a further confirmatory trial 
(the STalevo Reduction in Dyskinesia Evaluation [STRIDE-
PD] study) was designed with the aim of demonstrating 
that levodopa/carbidopa/entacapone, when used as initial 
levodopa therapy, significantly delayed the time to onset 
of dyskinesia compared with the conventional levodopa/
carbidopa formulation. Unfortunately, the STRIDE-PD 
trial failed to prove the benefit of continuous dopaminergic 
stimulation with triple therapy in clinical settings.73
Recently, studies describing the effects of combined 
COMT inhibition with levodopa administration in reducing 
homocysteine synthesis have been published. In this regard, 
clear evidence has been provided implicating homocysteine 
as a risk factor for vascular diseases, cognitive impairment, 
and dementia. It is an acknowledged fact that cerebrovascu-
lar diseases and cognitive impairment worsen the   prognosis 
of PD patients. Increased homocysteine in plasma has 
been reported in PD patients treated with levodopa applied 
only with a DDCI.74 This finding supports the onset of 
atherothrombotic disease in PD patients, as reported by 
  epidemiological studies.75,76 Several works have discussed the 
potential   benefits of peripheral COMT inhibition afforded by 
entacapone as adjunct to levodopa/DDCI in reducing plasma 
homocysteine levels. Although this hypothesis was not con-
firmed by several trials,77,78 other observations have demon-
strated how treatment with levodopa/carbidopa/entacapone 
  lowers homocysteine generation, reducing O-methylation of 
levodopa. In turn, the latter effects may positively influence 
the homocysteine-related progression of PD,74,79–81 while 
concomitantly decreasing the risk of cerebrovascular disease 
and cognitive impairment in parkinsonian patients.
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